mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy applications, but have also great potential as prophylactic vaccines.
Recently, mRNA vaccines have generated significant interest to complement or even replace traditional vaccines due to a number of important attributes that they possess. Although subunit vaccines have been used successfully to elicit humoral immunity against a wide variety of pathogens, they fail to induce cellular immunity which is required to eradicate the intra-cellular Live-attenuated vaccines are the most potent in activating both arms of the adaptive immune system -cellular and humoral immunity. However, these vaccines exhibit considerable safety drawbacks.
Indeed, attenuated pathogens have the very rare potential to revert to a pathogenic form and cause disease. This is of special concern in immune deficient individuals, or in immunosuppressed patients, where guidelines generally recommend that no live-attenuated vaccines should be administered. [1] Subunit vaccines have been developed as a safer alternative, while recognizing that they are less efficient and often require adjuvants.
With the vaccine limitations outlined above in mind, mRNA vaccines combine the advantages of subunit vaccines and live-attenuated vaccines without the risks associated with live-attenuated or DNA vaccines. Successful cytosolic delivery of mRNA, encoding for an antigen, results in vaccine epitope synthesis of the transfected cells. The presence of clearly defined antigens in the cytosol can enable presentation of both endogenous and exogenous antigens, and provide T cell activation while being safe. [2] [3] [4] The promise of activating the humoral and the cellular arms of the immune system has driven the development of DNA vaccines over the last decades. In fact, DNA and mRNA vaccines share many similarities, where the main difference between the two vaccines is the target location for the delivery of the oligonucleotides. DNA therapeutics have to reach the nucleus, while for mRNA F o r R e v i e w O n l y 3 industry for a long time. It was the development of RNA interference and its tremendous therapeutic potential that triggered intense efforts towards stabilization of RNA in vivo. Several strategies have been developed for RNA delivery, including RNA-conjugates, modified RNA, viral vectors, and microparticles and nanoparticles. [10] [11] [12] While linking RNA to molecules offers some level of protection against degradation, it can promote binding to serum proteins and subsequent aggregation that can lead to vascular blockage. [13] Viral delivery was the obvious choice for delivery, because viruses have naturally evolved to become highly efficient at nucleic-acid delivery.
However, several limitations are generally associated with these vectors, including immunogenicity, [14] carcinogenesis, [15] broad tropism, [16] packaging capacity, [17] and production difficulties. [18] In contrast to viral analogues, non-viral vectors exhibit significantly reduced transfection efficiency but tend to have lower immunogenicity than viruses, and patients do not have pre-existing immunity against the non-viral vector. Furthermore, non-viral vectors, whose sizes are larger that those of viruses, have the potential to carry larger genetic payloads, while at the same time being simple to synthesize. With the development of new materials and preparation techniques, as well as a better understanding of the mechanisms involved, non-viral vectors are becoming the preferred vehicle to deliver mRNA. [19] [20] [21] [22] The most common technologies use lipids,[23] polymers, [24] followed by peptides, [25] and inorganic nanoparticles. [26] Independent of the materials or technologies used, 'good' non-viral vectors should: (i) efficiently bind and condense RNA, (ii) protect against degradation in the extracellular space, and (iii) localize the payload at the membrane of the desired target cell, followed by (iv) cellular uptake, and (v) endosomal escape into the cytosol. This process, along with the barriers that need to be overcome, is outlined schematically in Figure 1a . Note that this is much more than what is needed for the delivery of protein or peptide antigens, where endocytosis is sufficient ( Figure 1b ). Currently, lipid nanoparticles (LNPs) are among the most frequently used vectors for in vivo RNA delivery. [27] Although most of the work on LNPs is aimed at treating genetic conditions in a number of different tissues, a considerable amount of work aims to target the immune system (Table 1) The most important targets for mRNA vaccines are professional antigen presenting cells (APCs), with dendritic cells (DCs) likely being the most relevant cell type. Indeed, DCs play a critical role in antigen processing and presentation to elicit an immune response against specific antigens. The transfected DCs express the mRNA-encoded antigen in the native form. The antigens are subsequently processed by the proteasome, and the generated peptide epitopes enter the endoplasmic reticulum where they are loaded onto major histocompatibility complex (MHC) class I molecules. The MHC class I molecules are transported to the surface of the cell where the epitopes are presented to CD8 T-cells along with co-stimulatory signals (Figure 2a ). Presentation of antigen fragments on MHC II induces antigen-specific antibodies. The MHC class II pathway may be This entire process is depicted schematically in Figure 2a , and has been thoroughly reviewed by Heath and Carbone. [28] Note that this is different from protein or peptide antigens which are degraded in the late endosome and loaded on MHCII for presentation to CD 4 T cells ( Figure 2b ).
There is a pathway for the presentation of protein antigens on MHCI termed cross-presentation.
However, this process is not yet fully understood, and is often too weak to elicit a potent cytotoxic immune response. [29] LNPs generally consist of an aqueous core surrounded by a lipid bilayer shell that is made of a combination of different lipids, each serving distinct functions.
[30] However, other structures have been reported. [31, 32] Most LNP formulations rely on cationic lipids to efficiently complex the negatively-charged RNA, although some anionic and neutral formulations have been used in the past. [23] Because several studies have shown that cationic lipids bearing a permanent positive charge are more toxic and less efficient, [33] the potency of LNPs has been advanced significantly with the development of new, ionizable lipids and lipid-like materials. [34] This new generation of lipids and lipidoids contains amine groups which maintain a neutral or mildly cationic surface charge at physiological pH, thereby reducing nonspecific lipid-protein interactions and facilitating oligonucleotide release in the cytosol. In the endosome, the amine groups are thought to be ionized upon acidification and help to induce hexagonal phase structures, which disrupt the membrane of the late endosomes. This, in turn, facilitates cellular uptake and endosomal escape of mRNA into the cytoplasm. [35, 36] Some of these ionizable lipids were identified by systematically modifying the polar head and non-polar tail structures of the lipids, [37] [38] [39] and others were discovered by combining large structural libraries into lipid-like lipidoids. [40] [41] [42] In addition to ionizable cationic lipids, phospholipids, cholesterol, and lipid-anchored polyethylene glycol (PEG) are the most commonly used components for LNP formulations. Generally, phospholipids play a structural role in LNPs. They help with the formation and disruption of the lipid bilayer to facilitate endosomal escape. Furthermore, some phospholipids possess polymorphic features and promote a transition from a lamellar to a hexagonal phase in the endosome. [ Indeed, water-soluble molecules, such as proteins and carbohydrates, can be entrapped within the LNP aqueous core, whereas lipophilic compounds can be incorporated into the LNP lipid bilayer. This, in turn, can facilitate the co-delivery of immunopotentiators, also known as adjuvants, which is important to enhance vaccine efficacy. [56, 57] The surface of a LNP may be decorated with specific targeting sequences which help with homing and subsequent uptake. LNPs could even be simultaneously formulated with multiple antigens, signaling factors, and adjuvants for tailored applications. Some of these LNP synthesis strategies are well established, and will be reviewed in the following section.
Synthesis of Lipid Nanoparticles
The method via which LNPs are synthesized is critical, because it directly affects both the LNP size and encapsulation efficiency. In general, LNPs are formed by condensing lipids from an ethanol solution in water. Depending on the LNP synthesis method, mRNA is dissolved in the aqueous phase and encapsulated in the condensation process, or is complexed to the finished LNPs in a second step. The theory of vesicle formation assumes that LNP formation is based on disk-like bilayered fragments whose edges are stabilized by ethanol. [58] When diluting ethanol in water, these planar fragments grow and fuse to even bigger rafts. At low ethanol concentrations, the destabilized structures bend to form closed LNPs. The faster the increase in the polarity of the ethanol solution, the smaller the fragments will be before closing into vesicles, resulting in overall smaller LNPs. Two important factors that directly influence the rate at which the polarity of the ethanol solution changes are the rate of mixing and the volumetric ratio between the aqueous and lipid phases. [59, 60] The mixing rate, for example, influences both the size and the homogeneity of the LNPs. The properties of individual LNPs strongly depend on local, microscopic mixing rates, where diffusive transport effects can lead to LNPs with variable compositions. Therefore, rapid mixing of the ethanol-lipid phase with excess water is key for the synthesis of small, uniform LNPs.
Early synthesis methods relied on the formation of micrometer-sized vesicles by suspending lipids in water, followed by sonication to produce submicrometer-sized particles. [61] This top-down approach has many limitations, including molecular degradation, contamination, and lack of scalability. Other synthesis methods include the condensation of a lipid ethanol solution by rapid injection into a vigorously stirred aqueous buffer. [62] The preformed vesicles are then complexed with RNA in slightly acidic ethanol-water solutions. [63, 64] However, this synthesis method lacks reproducibility due to variable injection and mixing rates. Extrusion of a lipid film through a small filter has also been a very popular synthesis method, and has often been used at the laboratory scale using syringe mini-extruders. [65] Newer synthesis methods directly mix the lipid-ethanol phase with an aqueous solution of mRNA in a small T-piece. [66] Here, the flow, and hence, the mixing rates, can be controlled with pumps. In this way, LNPs with diameters of 70nm or larger and high encapsulation efficiencies can be generated. [37] The macroscopic mixing techniques mentioned above enable a wide range of local mixing rates, leading to LNPs with high polydispersity and often poor reproducibility. Microfluidic mixing, such as, hydrodynamic flow focusing, was developed to generate more uniform particles. [67] However, with hydrodynamic flow focusing, small particles are only generated with ethanol-water flow ratios of 30 or higher, which leads to substantial dilution. [68] Higher mixing rates, with minimal mass transport effects, are achieved with staggered herringbone micro mixers, as depicted in Figure 3 . The staggered herringbone micromixer offers a number of advantages over other synthesis methods.
High encapsulation efficiency and the ability to generate small particles are among the most obvious advantages. Minimal material loss due to small dead volumes and low flow rate ratios are also important attributes for the synthesis of mRNA-LNPs. Furthermore, massive parallelization of the microfluidic device in a variety of materials is possible, enabling large scale, pharmaceuticalgrade synthesis. For these reasons, we expect that microfluidic mixing using the staggered herringbone structure will be one of the synthesis methods of choice going forward, for both small and large scale synthesis of LNPs and possibly other nanoparticle systems.
Targeting Antigen Presenting Cells
Decorating the LNPs with immune cell receptors may facilitate the uptake by the desired type of immune cells. For the immune system to be activated, or for an immune response to be elicited, professional APCs need to encounter an antigen and a danger signal. APCs are concentrated at high density in lymph nodes (LNs). For lymph node targeting, mRNA can be injected directly in the LNs, or LNPs can be designed to accumulate in the LNs. We will discuss direct LN injection in the next section, and focus here on the tailoring of LNPs for LN accumulation. The two most important parameters for LN accumulation are LNP size and surface composition. Generally, reports indicate decreasing lymphatic uptake with increasing LNP size. Only small LNPs with a diameter smaller than about 150 nm appear to enter the lymphatic capillaries, and are subsequently drained to the peripheral lymphatics. [71] [72] [73] On the other hand, larger LNPs are retained at the injection site. [74, 75] . Larger LNPs are believed to be recognized and cleared more rapidly by the complement system because they present a larger number of recognition sites on their surface. [76] Coating the particles with a PEG-containing lipid can reduce complement activation. The right amount of PEG coating on the LNPs is critical. A recent study by Carstens et al. showed that PEG coating clearly improves lymphatic drainage. A similar study by Kaur et al. came to the same conclusion for the LNPs that they considered. [77, 78] However, improved lymphatic drainage does not automatically translate in a more potent immune response. The observed enhancement in lymphatic drainage is possibly due to a higher shielding of the LNPs' cationic charges against unspecific interactions with proteins. [79] Interestingly, a higher PEG content in the LNPs is also known to adversely affect cellular LNP uptake via endocytosis and endosomal escape. [80, 81] It is well known that enhanced PEGylation of LNPs leads to longer blood circulation times. However, anti-PEG antibody response following repeated intravenous (IV) administration of PEGylated LNPs has been reported to dramatically accelerate blood clearance of the LNPs and to lead to acute hypersensitivity. [82, 83] This finding is very concerning for immunotherapy applications, where multiple dosing may be required for long-lasting protection. A possible solution may be found by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
Adjuvanting Lipid Nanoparticles
Adjuvants can be added readily to LNPs to increase the immune response. To this end, ongoing research needs to identify the best adjuvant candidates and effective doses. Aluminum salts were first used to enhance the immune response of traditional vaccines.
[94] The role of such adjuvants was initially related to the depot effect that prolonged antigen exposure, but is still not understood in detail. The LNP vector can have an adjuvant effect by itself.
[95] Some of the lipids can activate the immune system and are able to induce inflammation. Activation of the immune system is a problem for gene therapy delivery in protein replacement therapy, but is a desirable advantage for vaccination. In particular, LNPs containing cationic lipids, such as, 1,2-dioleyl-3trimethylammonium-propane chloride salt (DOTAP), have been shown to activate toll-like receptor 4 (TLR4) and induce a strong pro-inflammatory response with Th1 type cytokines, including IL-2, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 the medicinal chemistry potential of the pharma company Novartis to develop TLR agonists smallmolecule immune potentiators (SMIPs) to tune the immune activation and to limit side effects. [105] We would expect that small molecule TLR agonists could be tailored for formulation in LNPs, and produced at a much lower cost than many of the ligands used today.
However, there is growing evidence that the addition of non-mRNA adjuvants may not be necessary. Mammalian cells can sense foreign mRNA with so called pattern recognition receptors (PRR). These include the innate immune receptors TLR3, TLR7, and TLR8 that are located in the endosomes and sampling its content. [106] The cytosol is sampled for non-self mRNA by cytoplasmic innate immune receptors, the retinoic acid-inducible gene I (RIG-I), the protein kinase RNA-activated (PKR), 2'-5'-oligoadenylate synthase (OAS), and the melanoma differentiationassociated antigen 5 (MDA5). [107] Activation of these receptors results in upregulation of transcription of genes coding for type I interferons, proinflammatory cytokines: Interleukin-6 (IL-6), Il-12, tumor necrosis factor (TNF), and chemokines. Furthermore, via phosphorylation of eukaryotic translation initiation factor 2α (eiF2α), the protein translation will be slowed down and ultimately inhibited, [108] activation of OAS leads to overexpression of RNase L that degrades foreign and cellular RNA. [109] These receptor-mediated responses have evolved to protect cells from viral RNA and help mediate an antiviral immune response. For the purpose of mRNA mediated protein replacement therapy, this is a major problem that can be overcome by the use of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 10 naturally occurring modified nucleotides to suppress activation of these innate immune receptors. [110, 111] However, for vaccine applications, it remains to be determined weather modified mRNA, omitting stalled translation, and enhanced protein degradation, or unmodified mRNA activating the innate immune system will perform better.
A particularly innovative approach has been developed by the German biotech company CureVac, who tailored both mRNA stability and immunogenicity by optimizing the nucleotide sequence, and hence the codon sequence, while relying exclusively on unmodified nucleotides that translate into the same amino acid sequence. Their RNA adjuvant consists of a single-stranded, non-coding, noncapped RNA sequence containing several poly U-repeats that is complexed with a polymeric carrier to increase stability against degradation. [112] This general adjuvant not only increases the immunogenicity of mRNA vaccines, but also works for peptide and protein vaccines. [112, 113] An issue that has to be analyzed in detail is the fact that, through codon optimization, we do obtain the same full-length protein but a different set of cryptic peptides. Translation of alternative out of frame open reading frames or from alternative starts sites, including noncanonical triplets such as CUG, ACG, and GUG, lead to shorter so called cryptic peptides. [114] These shorter peptides are presented on MHC complexes and hence are alternative antigens for immune recognition. [115] These naturally occurring cryptic peptides may contribute to a therapeutic immune response, and may be lost upon codon optimization, as a different nucleotides sequence leads to a different set of cryptic peptides. [116] Although these optimized sequences are sufficiently stable to work without any vector, it remains to be seen if they would improve in efficiency if they are delivered in a LNP vector that helps with endosomal escape.
Routes of Administration
In order to mount a strong adaptive immune response, a vaccine needs to reach the LNs, where T cell activation and proliferation occurs. Furthermore, affinity maturation and isotype switching of antibodies takes place in germinal centers in the LNs. In order to target these sites, LNPs need to be tailored carefully. Properties like LNP composition, charge, size, and size distribution directly affect the pharmacokinetic characteristics and potency of the vector system. [117, 118] The route of administration likely influences both the immune response and side effects, and is therefore an important factor. Nevertheless, reports on the impact of the administration route on the quality and strength of the immune response are few, especially for mRNA-particle vaccines and even for protein-particle vaccines. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 11 Intramuscular injection (IM) of vaccines is the most often practiced route of administration in patients. Indeed, this route of vaccination is simple to carry out and does not require much training for its implementation. The second most practiced route of vaccine administration for routine vaccinations is subcutaneous injection (SC). The human subcutaneous tissue is tightly connected with its underlying bone and muscle tissues, making SC less practical for humans than for rodents.
It is straightforward for LNPs administered by either route to reach the LNs. Factors that determine lymphatic trafficking include particle size, charge, and colloidal stability. [119, 120] LNPs smaller than 150 nm are efficiently drained via afferent lymphatic vessels to the draining LNs. Also, larger LNPs are readily phagocytosed by immune cells and then trafficked to the LNs.
Intradermal injection (ID) delivers LNPs directly into the skin, an organ which is densely populated with Langerhans cells in the epidermis and with multiple DC subtypes in the dermis. The ID route of administration has been shown to effectively induce a Th1 type immune response and cytotoxic T-cell induction for mRNA-LNP vaccines. [121] Moreover, several studies with traditional vaccines have revealed that ID administration may require as little as one fifth of a standard IM dose to elicit a comparable immune responses. [122, 123] Together with recently developed transdermal drug delivery technologies like microneedles, ID applications may have great potential for dose sparing.
Intravenous injections (IV) of LNP-mRNA vaccines are less common because of the potential of systemic side effects. Indeed, injecting immunogenic material in the blood stream may lead to massive cytokine production, also known as cytokine storm, that can lead to shock and death. [116] Additionally, vital organs, including the liver and lungs, are transfected by mRNA vaccine delivery 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 However, for IN administration of mRNA vaccines, vectors may not be necessary. The intranodal injection of naked mRNA encoding antigens has been reported to induce a potent T cell response. [126] The challenge of intranodal immunization is the injection into the LN, which can be achieved using ultrasound guidance. [127] In spite of the obvious benefit, the additional equipment and need for specially-trained personnel will likely prevent direct LN injection from becoming widely adopted. Finally, reported intraperitoneal (IP) injection of an mRNA-LNP coding for betagalactosidase did not result in any significant immunization. [128] A recent study using LNPs with mRNA coding for luciferase compared different routes of administration. [129] The total amount of protein produced was largest for IV administration, while duration of luciferase expression was the longest for ID injection followed by IM administration.
How the route of administration of mRNA-LNPs influences both the total amount of protein produced, as well as the duration of expression, are two important parameters that have implications when determining a route of administration for a particular vaccine. A study investigating the different routes of administration in the context of both antibody titers and cytotoxic T cells would be very interesting.
Self-Amplifying mRNA
Self-amplifying mRNA has been used to prolong protein expression and to increase the immunogenicity of mRNA vaccines, which leads to a dramatic decrease in the effective dose compared to non-replicating mRNA. [130, 131] Self-amplifying mRNAs, also termed replicons, are based on RNA viruses where the structural viral proteins are replaced with suitable mRNA encoding antigens, as well as with RNA polymerases for RNA replication. The most studied replicons are derived from alphavirus and from flaviviruses. When introduced into the cytosol of cells, the mRNA will express the heterologous genes and replicate. Through the mRNA amplification, large amounts of desired antigens can be synthesized, accounting for up to 20% of total cell protein. [132] Self-amplifying mRNAs not only code for the antigens of interest, but also for the viral, RNA-dependent polymerase to amplify the replicon. As a result, self-amplifying mRNA is much larger than non-amplifying mRNA. The size of self-amplifying mRNA, including the 5' un-translated region, the poly-A tail, and the gene of interest, can be as large as 10kb.
Accordingly, delivery of self-amplifying mRNA requires a vector capable of transporting such a large payload. In this respect, LNPs have been used to successfully deliver self-amplifying 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 13 mRNA. [133, 134] Geall et al. showed that self-amplifying mRNA encapsulated in LNPs exhibits overall higher immunogenicity than the non-encapsulated variant. [134] However, it was not reported that SAM is more immunogenic than transient mRNA. For future applications in humans, the extent of immune response against the polymerase will need to be determined. Especially for repeated applications, an immune response against the polymerase could reduce the efficiency and be a safety issue.
Prophylactic and Therapeutic Vaccines
mRNA vaccines can be used for both prophylactic and therapeutic vaccination. The many advantages over protein or DNA vaccines enable the application of mRNA as a prophylactic against diseases where conventional vaccines have not shown sufficient efficacy. This is due to the nature of the immune activation and number of antigens that can be delivered. Because of the short production times, mRNA vaccines can also be used to respond rapidly to emerging threats or seasonal strains of pathogens. [133] Currently, no mRNA therapeutic is approved for use in humans, and a beneficial safety profile in patients still has to be demonstrated. A first clinical application will likely not be a prophylactic vaccine, because the tolerance for side effects is very low for a drug that is injected into healthy individuals. Establishing the safety profile in a therapeutic application, such as cancer immunotherapy, will be followed by prophylactic applications. Cancer immunotherapy appears to be an ideal application, because a strong CD8 T cell response is likely required to cure cancer, which is precisely the strength of mRNA vaccines. The feasibility of both prophylactic and therapeutic mRNA vaccines has been demonstrated in many pre-clinical studies.
While there have not been any clinical trials delivering mRNA vaccines with lipid nanoparticles, the results from two clinical trials have been reported. A phase 1/2 trial of protamine-complexed mRNA, coding for 6 different cancer associated antigens, delivered intradermally to metastatic melanoma patients, reported encouraging results. [135] In a phase 1/2a study, advanced prostate cancer patients treated with full length mRNA vaccine encoding for several tumor associated antigens, experience prolonged survival. [112] The vaccine was also administered intradermally and consisted of free modified mRNA and mRNA complexed with protamine.
Challenges in the Field and Future Perspectives
The field of mRNA therapeutics has entered a very exciting phase with multiple clinical studies ongoing using mRNA for cancer immunotherapy. Although no study yet employs LNP mRNA 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 14 formulations, LNPs offer a number of advantages over other vectors, including protection of nonstabilized mRNA, the large payload that can be delivered, adjuvants that can be co-delivered, the possibility to decorate them with targeting ligands, and the ease of simple synthesis.
We believe that valuable lessons can be learned from the clinical translation of siRNA-LNPs. Many of the components used in LNPs to deliver mRNA have also been used to deliver siRNA. Several clinical studies delivering siRNA in LNP carries have been conducted in recent years. [136] While the exact composition of formulations used to deliver the much larger mRNA molecules will likely be different from the ones used for siRNA, many of the challenges involved are the same. [137] Among the most problematic are the potential toxicity of LNP components, including cationic lipids, phospholipids, or combinations thereof. The immunogenicity of PEG, and the decreased interaction of the LNPs with the endosomal membranes that hinders endosomal escape, are also important issues for both siRNA and mRNA delivery.
The remaining challenges for LNP mRNA vaccines involve the complexity associated with identifying the best formulation. In this respect, a major challenge of all vaccine research is that antibody titers and T-cell counts are 'second order' effects, indicating that they are not a direct result of immune cell transfection, but instead, a result of how well these cells promote the immune response. Consequently, lymphatic drainage and transfection potency are not the only features that need to be considered. Two different LNPs, for example, may be able to drain to the lymphatics and transfect DCs exceptionally well. However, the measurable outcome may be completely different if one LNP fails to activate the appropriate signaling pathways that result in a complete immune response. Hence, there is currently no high-throughput assay to efficiently evaluate different formulations and to predict in vivo immune responses, as well as to address dosage and side effects.
Another challenge is that detailed mechanistic knowledge, e.g., of how LNPs assist in endocytosis and endosomal escape, is still lacking, thereby making the rational improvement or design of LNPs very difficult. For most formulations, the bottleneck has not been identified, whether it is endocytosis, endosomal escape, stability of the mRNA, DC activation, or something different.
Findings from protein or protein-LNP vaccines are only helpful to a certain extent, because antigen processing and presentation is completely different for mRNA-LNP vaccines. Even when optimizing the transfection efficiency of the LNPs, there are differences that need to be considered.
Another challenge is the definition of a standard for how the potency of LNP formulations should be determined. For this purpose, the community uses different administration routes and different antigens at variable time points. Much like the expression of luciferase is a standard for mRNAbased protein replacement therapeutics, the mRNA vaccine community needs to establish its own standards. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 15 Besides improvements to the vector, the community should not forget the payload itself. The true power of mRNA-LNPs over naked mRNA is the co-administration of various different signals to the same cell, as well as the decoration of the LNPs with targeting ligands. LNPs need to be developed further to potentiate this advantage and live up to their full potential. Furthermore, it is still unclear how the different administration routes behave for LNP-based mRNA vaccines. A comparative evaluation of LNPs is required for several administration routes to determine the optimal parameters for the desired vaccination.
Finally, mRNA vaccines will have to demonstrate that they are superior to DNA vaccines, and that there is not a significant reduction in potency upon translation from small animal models to humans.
The first DNA vaccine entered clinical trials almost 20 years ago without a single product licensed for use in humans. [138] This is in part because the potency of DNA vaccines in humans has been lower than that suggested by preclinical studies in small animals. [139] A major advantage of mRNA vaccines over DNA vaccines is regulatory in nature. Both the regulatory agencies in the US and Germany, namely, the FDA, and the Paul Ehrlich Institute, respectively, do not classify nonreplicating mRNA as gene therapy. This, in turn, eases the requirements for preclinical and toxicological studies. [140] mRNA vaccines represent a very exciting application with multiple clinical-stage applications. Currently, no LNP-mRNA vaccine has been tested in patients, because there are still a number of unanswered questions. Nevertheless, we believe that addressing these questions, including LNP composition, co-delivered adjuvants, and decoration with targeting ligands, will uncover the true potential of LNP-formulations over other delivery vectors.
Executive Summary

Differences between DNA and mRNA vaccines
• mRNA vaccines, like DNA vaccines, induce synthesis of antigens in transfected cells, and hence, activate a broad immune response, including antibodies, Th1 helper CD4 T cells, and cytotoxic CD8 T cells.
• mRNA, with the cytosol as its target, is easier to deliver and much safer than DNA, because the mRNA in the cytosol does not interact with the genome in the nucleus and is only transiently expressed.
• In contrast to DNA vaccines, the FDA does not consider non-replicating mRNA vaccines gene therapies.
Advantages and challenges of lipid nanoparticles (LNPs)
• LNPs protect the mRNA against degradation and assist in endocytosis and endosomal escape.
• Adjuvants can be incorporated in LNPs and assist in immune activation and potentially 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 • LNPs can be targeted to specific cell types by decorating their surfaces with specific ligands.
• LNP synthesis, using methods such as microfluidic devices, is robust and up-scalable.
• Some cationic lipidoids exhibit toxicity, and repeated application can induce an immune response against PEG.
Future perspectives of LNP mRNA vaccines
• mRNA vaccines are currently evaluated in clinical trials, albeit not formulated in LNPs.
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